Funder
Bristol-Myers Squibb
Beijing Xisike Clinical Oncology Research Foundation
Reference46 articles.
1. A global view of hepatocellular carcinoma: trends, risk, prevention and management;Yang;Nat Rev Gastroenterol Hepatol,2019
2. Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology;Benson;J Natl Compr Canc Netw,2021
3. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial;El-Khoueiry;Lancet,2017
4. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial;Yau;Lancet Oncol,2022
5. FDA approval summary: atezolizumab plus bevacizumab for the treatment of patients with advanced unresectable or metastatic hepatocellular carcinoma;Casak;Clin Cancer Res,2021
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献